<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8935">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02990637</url>
  </required_header>
  <id_info>
    <org_study_id>163004</org_study_id>
    <nct_id>NCT02990637</nct_id>
  </id_info>
  <brief_title>The Effect of Olive Leaf Extract Administration on Cardiovascular Health</brief_title>
  <official_title>The Effect of Olive Leaf Extract Administration on Cardiovascular Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of daily supplementation of OLECOL
      for a period of 8 weeks on cardiovascular risk markers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood lipid profile</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid peroxidation</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Overweight and Obesity</condition>
  <condition>Elevated Cholesterol</condition>
  <arm_group>
    <arm_group_label>OLECOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olive leaf extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OLECOL</intervention_name>
    <description>Olive leaf extract</description>
    <arm_group_label>OLECOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy individuals

          -  Age between 18 and 70 years

          -  Total cholesterol levels â‰¥ 5.0 mmol/L

          -  BMI 25-35 kg/m2

        Exclusion Criteria:

          -  History of severe cardiovascular, respiratory, urogenital, gastrointestinal/hepatic,
             hematological/immunologic, HEENT (head, ears, eyes, nose, throat).
             Dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine,
             neurological diseases, allergy, major surgery and /or laboratory assessments that
             might limit participation in or completion of the study protocol.

          -  Diabetes

          -  Use of medication that might have influence on endpoints (e.g. cholesterol lowering
             medication, hypertension medication)

          -  Administration of investigational drugs or participation in any scientific
             intervention study which may interfere with this study in the 180 days prior to the
             study

          -  Use of antibiotics in the 30 days prior to the start of the study

          -  Use of antioxidants, minerals and vitamin supplements available in pharmacies,
             drugstores, food markets or in alternative medicine

          -  Pregnancy, lactation

          -  Abuse of products (&gt; 20 alcoholic consumptions per week and drugs)

          -  Smoking

          -  Weight gain or loss (&gt; 3 kg in previous 3 months)

          -  High physical activity (&gt;4.5 hours of running/week)

          -  History of any side effects towards intake of olives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yala Stevens, MSc</last_name>
    <phone>0031433884295</phone>
    <email>yala.stevens@maastrichtuniversity.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yala Stevens, MSc</last_name>
      <email>yala.stevens@maastrichtuniversity.nl</email>
    </contact>
    <investigator>
      <last_name>Ad Masclee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 13, 2016</lastchanged_date>
  <firstreceived_date>December 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Yala Stevens</investigator_full_name>
    <investigator_title>MSc.</investigator_title>
  </responsible_party>
  <keyword>Olive leaf extract</keyword>
  <keyword>Cardiovascular health</keyword>
  <keyword>Cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
